Cargando…

Myeloid cell leukemia-1 is an important predictor of survival and progression of small cell lung cancer

BACKGROUND: Small cell lung cancer (SCLC) is the most fatal malignancy for which more effective therapies are urgently needed. Overexpression of myeloid cell leukemia-1 (Mcl-1) has been demonstrated to be one of the most common genetic alterations among different types of tumor/cancer, which induces...

Descripción completa

Detalles Bibliográficos
Autores principales:	Zhou, Ting, Zhang, Lin, Liu, Tingting, Yang, Yunpeng, Luo, Fan, Zhang, Zhonghan, Huang, Yan, Zhao, Hongyun, Zhang, Li, Zhao, Yuanyuan
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	AME Publishing Company 2020
Materias:	Original Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7791257/ https://www.ncbi.nlm.nih.gov/pubmed/33437788 http://dx.doi.org/10.21037/atm-20-2305

Ejemplares similares

Effects of thoracic radiotherapy timing and duration on progression‐free survival in limited‐stage small cell lung cancer
por: Zhao, Shen, et al.
Publicado: (2018)

Comparison of First-Line Treatments for Patients With Extensive-Stage Small Cell Lung Cancer: A Systematic Review and Network Meta-analysis
por: Zhou, Ting, et al.
Publicado: (2020)

Clinical Significance of Kinetics of Low-Density Lipoprotein Cholesterol and Its Prognostic Value in Limited Stage Small Cell Lung Cancer Patients
por: Liu, Tingting, et al.
Publicado: (2021)

The ACTIVE study protocol: apatinib or placebo plus gefitinib as first-line treatment for patients with EGFR-mutant advanced non-small cell lung cancer (CTONG1706)
por: Zhang, Zhonghan, et al.
Publicado: (2019)

Dual blockade of EGFR and VEGFR pathways: Results from a pilot study evaluating apatinib plus gefitinib as a first‐line treatment for advanced EGFR‐mutant non‐small cell lung cancer
por: Zhang, Zhonghan, et al.
Publicado: (2020)

Molecular predictors of post-transplant survival in acute myeloid leukemia
por: Qin, Tong, et al.
Publicado: (2017)

Efficacy and Tolerability of Erlotinib 100 mg/d vs. Gefitinib 250 mg/d in EGFR-Mutated Advanced Non-small Cell Lung Cancer (E100VG250): An Open-Label, Randomized, Phase 2 Study
por: Zhao, Shen, et al.
Publicado: (2020)

Ratio of C-Reactive Protein/Albumin is An Inflammatory Prognostic Score for Predicting Overall Survival of Patients with Small-cell Lung Cancer
por: Zhou, Ting, et al.
Publicado: (2015)

Pemetrexed/carboplatin plus gefitinib as a first-line treatment for EGFR-mutant advanced nonsmall cell lung cancer: a Bayesian network meta-analysis
por: Zhang, Zhonghan, et al.
Publicado: (2019)

Utility of comprehensive genomic profiling in directing treatment and improving patient outcomes in advanced non-small cell lung cancer
por: Zhao, Shen, et al.
Publicado: (2021)

Serum low-density lipoprotein and low-density lipoprotein expression level at diagnosis are favorable prognostic factors in patients with small-cell lung cancer (SCLC)
por: Zhou, Ting, et al.
Publicado: (2017)

Differentiation and Cell Survival of Myeloid Leukemia Cells
por: Studzinski, George P., et al.
Publicado: (2012)

Determinants of survival in advanced non-small cell lung cancer patients treated with anti-PD-1/PD-L1 therapy
por: Ali, Wael Abdullah Sultan, et al.
Publicado: (2021)

Comparison of the Prognostic Value of Systemic Inflammation Response Markers in Small Cell Lung Cancer Patients
por: Zhou, Ting, et al.
Publicado: (2019)

Continuation of anti-PD-1 therapy plus physician-choice treatment beyond first progression is not associated with clinical benefit in patients with advanced non-small cell lung cancer
por: Wang, Yixing, et al.
Publicado: (2023)

EGFR T790M relative mutation purity predicts osimertinib treatment efficacy in non-small cell lung cancer patients
por: Zheng, Qiufan, et al.
Publicado: (2020)

Hyper-SUMOylation of ERG Is Essential for the Progression of Acute Myeloid Leukemia
por: Chen, Xu, et al.
Publicado: (2021)

Optimal tumor shrinkage predicts long-term outcome in advanced nonsmall cell lung cancer (NSCLC) treated with target therapy: Result from 3 clinical trials of advanced NSCLC by 1 institution
por: He, Xiaobo, et al.
Publicado: (2016)

The comparison of EGFR-TKI failure modes and subsequent management between exon 19 deletion and exon 21 L858R mutation in advanced non-small-cell lung cancer
por: Zhang, Yaxiong, et al.
Publicado: (2017)

PRL2 inhibition elevates PTEN protein and ameliorates progression of acute myeloid leukemia
por: Carlock, Colin, et al.
Publicado: (2023)

Impact of prior cancer history on the overall survival of younger patients with lung cancer
por: Liu, Jiaqing, et al.
Publicado: (2020)

p300 promotes proliferation, migration, and invasion via inducing epithelial-mesenchymal transition in non-small cell lung cancer cells
por: Hou, Xue, et al.
Publicado: (2018)

Chronic Myeloid Leukemia in Nigerian Patients: Anemia is an Independent Predictor of Overall Survival
por: Oyekunle, Anthony A., et al.
Publicado: (2016)

Retraction Note: p300 promotes proliferation, migration, and invasion via inducing epithelial-mesenchymal transition in non-small cell lung cancer cells
por: Hou, Xue, et al.
Publicado: (2023)

Afatinib as a Potential Therapeutic Option for Patients With NSCLC With EGFR G724S
por: Wei, Yang, et al.
Publicado: (2021)

Accelerated phase chronic myeloid leukemia: evaluation of clinical criteria as predictors of survival, major cytogenetic response and progression to blast phase
por: Furtado, Vanessa Fiorini, et al.
Publicado: (2015)

Chimeric Antigen Receptor T Cells Targeting Cell Surface GRP78 to Eradicate Acute Myeloid Leukemia
por: Yu, Wei, et al.
Publicado: (2022)

The Important Role of Immunotherapies in Acute Myeloid Leukemia
por: Greiner, Jochen
Publicado: (2019)

Mitochondrial oxidative phosphorylation is dispensable for survival of CD34(+) chronic myeloid leukemia stem and progenitor cells
por: Yan, Jin-Song, et al.
Publicado: (2022)

T cell receptor excision circles are potential predictors of survival in adult allogeneic hematopoietic stem cell transplantation recipients with acute myeloid leukemia
por: Söderström, Anna, et al.
Publicado: (2022)

Progression-Free Survival: An Important Prognostic Marker for Long-Term Survival of Small Cell Lung Cancer
por: Park, Myoung-Rin, et al.
Publicado: (2014)

Runt-Related Transcription Factor 3 Promotes Acute Myeloid Leukemia Progression
por: Zhang, Wenwen, et al.
Publicado: (2021)

Increased PD-1(+)Foxp3(+) γδ T cells associate with poor overall survival for patients with acute myeloid leukemia
por: Zheng, Jiamian, et al.
Publicado: (2022)

Response Rates as Predictors of Overall Survival: A Meta-Analysis of Acute Myeloid Leukemia Trials
por: Agarwal, Suresh K., et al.
Publicado: (2017)

Stem Cell Biomarkers in Chronic Myeloid Leukemia
por: Jiang, Xiaoyan, et al.
Publicado: (2008)

Cholesterol synthesis disruption combined with a molecule-targeted drug is a promising metabolic therapy for EGFR mutant non-small cell lung cancer
por: Luo, Youli, et al.
Publicado: (2021)

HMGB1: an important regulator of myeloid differentiation and acute myeloid leukemia as well as a promising therapeutic target
por: Liu, Lulu, et al.
Publicado: (2020)

IGFBP7 induces apoptosis of acute myeloid leukemia cells and synergizes with chemotherapy in suppression of leukemia cell survival
por: Verhagen, H JMP, et al.
Publicado: (2014)

The correlations of tumor mutational burden among single-region tissue, multi-region tissues and blood in non-small cell lung cancer
por: Zhang, Yaxiong, et al.
Publicado: (2019)

Myelodysplastic Syndrome Progression to Acute Myeloid Leukemia at the Stem Cell Level
por: Chen, Jiahao, et al.
Publicado: (2018)

Cannot write session to /tmp/vufind_sessions/sess_l1oas9ogms6n2ic01ovn88osuj